GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cingulate Inc (NAS:CING) » Definitions » ROE % Adjusted to Book Value

Cingulate (Cingulate) ROE % Adjusted to Book Value : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cingulate ROE % Adjusted to Book Value?

Cingulate's ROE % for the quarter that ended in Mar. 2024 was 0.00%. Cingulate's PB Ratio for the quarter that ended in Mar. 2024 was 1.71. Cingulate's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 0.00%.

Cingulate ROE % Adjusted to Book Value Historical Data

The historical data trend for Cingulate's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cingulate ROE % Adjusted to Book Value Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - -124.75 -49.13 -

Cingulate Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.95 - - - -

Competitive Comparison of Cingulate's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Cingulate's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cingulate's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cingulate's ROE % Adjusted to Book Value falls into.


Cingulate ROE % Adjusted to Book Value Calculation

Cingulate's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Cingulate's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 1.71
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cingulate ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cingulate's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Cingulate (Cingulate) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cingulate Inc (NAS:CING) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
EVLO APM KTTA PULM IMPL RNAZ TRVN IBIO PYPD BCLI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
1901 W. 47th Place, Kansas, KS, USA, 66205
Website
https://www.cingulate.com
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Executives
Jennifer L. Callahan officer: Corporate Controller C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Peter J. Werth director, 10 percent owner C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Shane J. Schaffer director, 10 percent owner, officer: Chief Executive Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Craig S. Gilgallon officer: EVP & General Counsel C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Laurie Myers officer: EVP & Chief Operating Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Gregg Wm Givens director C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Scott Applebaum director C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Curtis Medeiros director 2120 COLORADO AVE., SUITE 230, SANTA MONICA CA 90404
Van Horn Louis G officer: EVP & Chief Financial Officer C/O CINGULATE THERAPEUTICS, 1901 W. 47TH PLACE, THIRD FLOOR, KANSAS CITY KS 66205
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Jeffrey X Conroy director 2372 MORSE AVE, IRVINE CA 92614
Thomas Jeffrey Hargroves director C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Raul R. Silva officer: EVP & Chief Science Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Matthew Brams officer: EVP & Chief Medical Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Fountainhead Shrugged, Llc 10 percent owner 1901 W. 47TH PLACE, #310, KANSAS CITY KS 66205